Highlights

  • Fiscal third quarter 2026 net sales were $570.1 million, compared with $560.4 million, with diluted EPS of $0.26.
  • Net earnings from continuing operations were $12.3 million, compared with $21.5 million, and operating income was $25.0 million.
  • The Feminine Care sale to Essity closed on February 2, 2026, with proceeds of approximately $340 million.
  • Management expects fiscal 2026 adjusted EPS of $1.80 to $2.00 and adjusted EBITDA of $250 million to $260 million.

Edgewell Personal Care Company (NYSE: EPC) shares were trading at USD 27.94 on October 27, 2026, down 0.04%, with a relative volume at time of 2.05. The personal care company closed the sale of its Feminine Care segment on February 2, 2026, declared a quarterly dividend of $0.15 per share on August 5, 2026, and reported third quarter fiscal 2026 results with narrowed full-year guidance.

Edgewell Personal Care is incorporated in Missouri, and its principal executive offices are at 6 Research Drive in Shelton, Connecticut. It reports two segments organized by product. Wet Shave includes razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care includes sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products. The former Feminine Care segment is presented as discontinued operations. Its fiscal year ends September 30.

Third Quarter Fiscal 2026 Results

The Form 10-Q covers the quarter ended June 30, 2026 and reports unaudited results from continuing operations unless noted. Net sales increased $9.7 million, or 1.7%, to $570.1 million, and organic net sales, a non-GAAP measure, increased 1.1%. North America organic sales increased 3.0%, and international organic sales declined 1.4%, which the company attributed primarily to temporary disruption associated with the conflict in the Middle East and short-term supply chain impacts related to the Wet Shave manufacturing consolidation.

Wet Shave net sales were $312.8 million, compared with $317.0 million, and Sun and Skin Care net sales were $257.3 million, compared with $243.4 million. Gross profit was $242.5 million, compared with $250.1 million, and gross margin decreased 210 basis points to 42.5%. SG&A expense was $108.3 million, compared with $100.7 million.

Operating income was $25.0 million, compared with $45.0 million. Net earnings from continuing operations were $12.3 million, or $0.26 per diluted share, compared with $21.5 million, or $0.46. Restructuring charges were $12.7 million. On a non-GAAP basis, adjusted diluted EPS from continuing operations was $0.72, unchanged from the prior year quarter.

For the first nine months, net sales were $1,512.4 million, and the net loss from continuing operations was $12.9 million, or $0.28 per diluted share, compared with net earnings of $32.1 million, or $0.67.

Balance Sheet, Debt and Cash Flow

At June 30, 2026, Edgewell had cash of $397.1 million and total borrowings of $1,284.2 million, including $1,250.0 million of fixed-rate long-term notes. Revolver borrowings were zero, compared with $140.0 million at September 30, 2025, and $418.8 million was available under the revolver. The company used proceeds from the Feminine Care sale to repay all outstanding borrowings under its U.S. revolving credit facility and estimates approximately $55 million of cash taxes in fiscal 2026 on the tax gain.

Cash flow from operating activities was $47.1 million for the first nine months, compared with $44.3 million. Dividend payments totaled $21.5 million, and share repurchases were $15.8 million. The company stated that it was in compliance with its debt covenants and believes its liquidity is sufficient for at least the next 12 months.

Fiscal 2026 Outlook

On the August 5, 2026 call, management said it expects fiscal 2026 organic net sales of flat to 0.5% growth, narrowed from a range of a 1.0% decrease to a 2.0% increase. It expects adjusted EPS of $1.80 to $2.00, compared with the prior range of $1.70 to $2.10, and adjusted EBITDA of $250 million to $260 million, narrowed from $245 million to $265 million. It expects adjusted free cash flow of $80 million to $110 million, excluding the impacts of the Feminine Care divestiture. These are non-GAAP measures.

Management also said it expects restructuring and related costs of approximately $92 million for fiscal 2026, primarily supporting the Wet Shave manufacturing consolidation. It said the project has created temporary disruption as production is transitioned across the network.